Telix at Bell Potter Healthcare Conference: growth, supply and pipeline
On November 17, 2026, Telix Pharmaceuticals (TLX) presented its expanding business at the Bell Potter Healthcare Conference. The company highlighted increasing revenue, product launches, and a strengthened supply chain while acknowledging the costly nature of radiopharmaceuticals and the need for robust clinical support. Management discussed the sector's expansion phase, emphasizing Telix's approved products, late-stage pipeline, and global manufacturing capabilities.
The company forecasted 2026 revenue to reach approximately $1 billion, equivalent to AUD 1.4 billion. Radiopharma, the industry sector, was projected to experience "hypergrowth," with manufacturing and commercial scale becoming crucial. BiPASS, a biopsy avoidance study, was expected to yield results in Q1 2025, with an FDA filing in Q2 2025 under fast-track status.
Pixclara, a fluoroethyltyrosine FET PET product, had FDA approval in September 2024 and was commercially available under a temporary NOC code. A favorable reimbursement code was anticipated in Q1 2025. The ITM Group acquisition aimed to secure lutetium-177 supply and broaden the product portfolio. Telix's precision medicine division was on track for substantial growth, with 2026 revenue expected to approach $1 billion, representing over 25% year-over-year growth.
The company's latest 12-month revenue of $891 million indicated a 33.5% growth, surpassing management's guidance while maintaining a gross profit margin of nearly 48%. The majority of revenue was slated for reinvestment in research and development and commercial infrastructure. Telix operated in 22 countries with a focus on three FDA-approved precision medicine products and a global network of 45 manufacturing sites for radioactive product production.
Dr. David Cade, Telix's Group Chief Medical Officer, emphasized BiPASS, a study aiming to reduce or eliminate the need for prostate biopsies through gallium-68 PSMA PET imaging combined with MRI. Enrollment concluded in June 2024, with data expected in Q1 2025. The FDA granted fast-track designation, and a de novo application was planned for Q2 2025.
Dr. Cade outlined a two-step future for prostate imaging: "none and done," avoiding biopsies altogether, and "one and done," using imaging to guide targeted biopsy. Telix also discussed Pixclara and its potential expansion into brain metastases, noting the market size as about 10 times larger than primary brain cancer.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.